Diagnostik und Therapie der zerebralen Venen- und Sinusthrombose

Auch wenn die zerebrale Venen-/Sinusthrombose (CVST) eine seltene zerebrovaskuläre Erkrankung darstellt, wird sie zunehmend häufiger diagnostiziert aufgrund erhöhter klinischer Aufmerksamkeit, besserer Bildgebungsmöglichkeiten sowie einer höheren Überlebensrate von Patienten mit prädisponierenden Erkrankungen. Dieser Beitrag zeigt, wie die Diagnose effektiv gestellt werden kann und welche Therapieoptionen in der Akutphase und Sekundärprophylaxe bestehen.

Although cerebral venous and sinus thrombosis (CVST) is a rare cerebrovascular disease, it is being diagnosed with increasing frequency due to increased clinical awareness, better imaging capabilities, and higher survival rates in patients with predisposing conditions. This article shows how the diagnosis can be made effectively and what therapeutic options exist in the acute phase and secondary prophylaxis.

Schlüsselwörter

Sinusthrombose - Venenthrombose - Koagulopathie - Antikoagulation - Prophylaxe

Keywords

sinus thrombosis - cerebral venous thrombosis - coagulopathy - anticoagulation

Publication History

Article published online:
15 April 2021

• Literatur

• 1 Coutinho JM, Zuurbier SM, Aramideh M. et al. The incidence of cerebral venous thrombosis: a cross-sectional study. Stroke 2012; 43: 3375-3377
• 2 Bousser MG, Crassard I. Cerebral venous thrombosis, pregnancy and oral contraceptives. Thromb Res 2012; 130 (Suppl. 01) S19-22
• 3 Gameiro J, Ferro JM, Canhao P. et al. Prognosis of cerebral vein thrombosis presenting as isolated headache: early vs. late diagnosis. Cephalalgia 2012; 32: 407-412
• 4 Ferro JM, Canhao P, Stam J. et al. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke 2004; 35: 664-670
• 5 Chik Y, Gottesman RF, Zeiler SR. et al. Differentiation of transverse sinus thrombosis from congenitally atretic cerebral transverse sinus with CT. Stroke 2012; 43: 1968-1970
• 6 Stam J, de Bruijn S, deVeber G. Anticoagulation for cerebral sinus thrombosis. Cochrane Database Syst Rev 2008 (08) : CD002005
• 7 Ferro JM, Bousser MG, Canhao P. et al. European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis – endorsed by the European Academy of Neurology. Eur J Neurol 2017; 24: 1203-1213.
• 8 Arbeitsgemeinschaft Wissenschaftlich-Medizinischer Fachgesellschaften – AWMF. Diagnostik und Therapie der Venenthrombose und der Lungenembolie. Stand: 10.10.2015, gültig bis 09.10.2020. AWMF-Leitlinienregister 065 / 002 Im Internet:. https://www.awmf.org/leitlinien/detail/ll/065–002.html (Stand: 15. 01.2021)
• 9 Lebas A, Chabrier S, Fluss J. et al. EPNS / SFNP guideline on the anticoagulant treatment of cerebral sinovenous thrombosis in children and neonates. Eur J Paediatr Neurol 2012; 16: 219-228
• 10 Coutinho JM, Zuurbier SM, Bousser MG, Ji X, Canhao P, Roos YB. et al. Effect of Endovascular Treatment With Medical Management vs Standard Care on Severe Cerebral Venous Thrombosis: The TO-ACT Randomized Clinical Trial. JAMA Neurol. 2020; ;8; 77 (08) 966-973
• 11 Dentali F, Squizzato A, Gianni M. et al. Safety of thrombolysis in cerebral venous thrombosis. A systematic review of the literature. Thromb Haemost 2010; 104: 1055-1062
• 12 Dentali F, Poli D, Scoditti U. et al. Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study. J Thromb Haemost 2012; 10: 1297-1302
• 13 Ferro JM, Coutinho JM, Dentali F, Kobayashi A, Alasheev A, Canhao P. et al. Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis: A Randomized Clinical Trial. JAMA Neurol. 2019; ; 3; 76 (12) 1457-1465.
• 14 Bousser MG, Ferro JM. Cerebral venous thrombosis: an update. Lancet Neurol 2007; 6: 162-170
• 15 Bugnicourt JM, Guegan-Massardier E, Roussel M. et al. Cognitive impairment after cerebral venous thrombosis: a two-center study. J Neurol 2013; 260: 1324-1331
• 16 Saposnik G, Barinagarrementeria F, Brown Jr RD. et al. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association / American Stroke Association. Stroke 2011; 42: 1158-1192
• 17 Masuhr F, Busch M, Amberger N. et al. Risk and predictors of early epileptic seizures in acute cerebral venous and sinus thrombosis. Eur J Neurol 2006; 13: 852-856
• 18 Ferro JM, Canhao P, Bousser MG. et al. Early seizures in cerebral vein and dural sinus thrombosis: risk factors and role of antiepileptics. Stroke 2008; 39: 1152-1158
• 19 Ferro JM, Correia M, Rosas MJ. et al. Seizures in cerebral vein and dural sinus thrombosis. Cerebrovasc Dis 2003; 15: 78-83
• 20 Palazzo P, Agius P, Ingrand P. et al. Venous thrombotic recurrence after cerebral venous thrombosis: a long-term follow-up study. Stroke 2017; 48: 321-326.
• 21 Arbeitsgemeinschaft Wissenschaftlich-Medizinischer Fachgesellschaften – AWMF. Prophylaxe der venösen Thromboembolie (VTE). Stand: 15.10.2015, gültig bis 14.10.2020. AWMF-Leitlinienregister 003 / 001. Im Internet:. https://www.awmf.org/leitlinien/detail/ll/003–001.html (Stand: 15.01.2021)
• 22 Monagle P, Chalmers E, Chan A. et al. Antithrombotic therapy in neonates and children. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, 8th edn. Chest 2008; 133: 887S-968S
• 23 Aguiar de Sousa D. Canhao P, Ferro JM. Safety of pregnancy after cerebral venous thrombosis: a systematic review. Stroke 2016; 47: 713-718.
• 24 Bain E, Wilson A, Tooher R. et al. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database Syst Rev 2014; 2 (02) CD001689.